Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

• Status: Completed
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind, placebo-controlled study of oral cromolyn sodium when made into a viscous preparation for the treatment of eosinophilic esophagitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Tennessee
• Treatments: Cromolyn Sodium

Criteria

Inclusion Criteria:

• Diagnosis of eosinophilic esophagitis

Exclusion Criteria:

• Concomitant treatment with swallowed corticosteroids. Any prior use of swallowed corticosteroids will require a 4 week washout period.

• Pregnancy (all females of child bearing potential will have urine pregnancy test done at baseline).

• Evidence of pathologic eosinophilia in other locations in the GI tract.

• Participation in another research protocol

• Reduced Renal or Hepatic Function (all subjects will have a baseline creatinine and liver function panel drawn)